Structured evidence table for Citicoline Memory Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Citicoline Memory Randomized Trial | Various pharmacological and nonpharmacological interventions have been introduced, but the evidence regarding their efficacy, safety, and tolerability is conflicting and inconsistent. | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Citicoline Memory Randomized Trial | This could be attributed to a decline in the efficacy of ChE-Is treatment over time, and to the difficulty in treating specific patient categories such as older age groups, or patients with the concomitant presence of conditions such as bradycardia, bronchial asthma, or chronic obstructive pulmonary disease due to the treatment-associated adverse effects (,). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Citicoline Memory Randomized Trial | Studies were classified based on the quality assessment into three categories: low-risk bias (all quality criteria met), moderate-risk bias (one or more quality criteria only partly met), and high-risk bias (one or more quality criteria not met). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Citicoline Memory Randomized Trial | 1 2 3 4 5 6 Dementia is a condition linked to various neurodegenerative diseases, marked by a significant decline in cognitive abilities that affects daily activities (). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Citicoline Memory Randomized Trial | Under normal conditions, it is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Keap1), which targets it for degradation []. | 4 | Cipriano Giovanni Luca (2026) | Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy |
| Citicoline Memory Randomized Trial | The following subsections provide a detailed analysis of the molecular profiles and clinical evidence for these three primary bioactives. | 4 | Cipriano Giovanni Luca (2026) | Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy |
| Citicoline Memory Randomized Trial | In elderly patients with mild cognitive impairment (MCI), 16 weeks of Lion’s Mane supplementation significantly improved cognitive scores, with a subsequent decline observed once supplementation ceased, emphasizing its role in maintaining functional neural connectivity []. | 4 | Cipriano Giovanni Luca (2026) | Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy |
| Citicoline Memory Randomized Trial | 1 2 3 4 5 6 The global increase in life expectancy has led to a parallel rise in the prevalence of neurodegenerative diseases and age-related cognitive decline [,], establishing brain health as a paramount priority in contemporary biomedical research. | 4 | Cipriano Giovanni Luca (2026) | Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy |
Source documents